A.M. Vitals: Roche Bids $5.7 Billion For Illumina
Hostile Bid For Illumina: Swiss drug maker Roche is making a $44.50 per-share hostile bid for Illumina, valuing the gene-sequencing company at $5.7 billion, the WSJ reports. Illumina has already rejected an offer of $40 per share, Roche says. The latest bid represents a premium of about 18% to Illumina’s $37.69 closing price Tuesday. Illumina said today it would review Roche’s proposal.
PFCs and Vaccines: A study published in the Journal of the American Medical Association finds that increased exposure to chemicals known as PFCs is associated with a weaker immune response to the tetanus and diphtheria vaccines in children, NPR’s Shots blog reports. PFCs, some of which have been phased out by the EPA, are found in some food containers, non-stick coatings and stain-resistant fabrics, NPR reports.
WellPoint Earnings: WellPoint’s fourth-quarter earnings fell 39% to $335.3 million, or 96 cents per share, due to investment losses and higher costs, the WSJ reports. Excluding special items, earnings fell to 99 cents. Analysts surveyed by Thomson Reuters had expected earnings of $1.12. Revenue rose 5.5% to $15.18 billion, less than the $15.41 billion expected by analysts.
Grieving as Depression?: There’s controversy over the American Psychiatric Association’s proposed revision to the diagnosis […]
Read more this great post here
